Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.03.2009 | Preclinical Study

Functional identification of genes causing estrogen independence of human breast cancer cells

verfasst von: Ton van Agthoven, Jos Veldscholte, Marcel Smid, Thecla L. A. van Agthoven, Lilian Vreede, Marieke Broertjes, Ingrid de Vries, Danielle de Jong, Roya Sarwari, Lambert C. J. Dorssers

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Endocrine treatment of breast cancer is widely applied and effective. However, in advanced disease cases, the tumors will eventually progress into an estrogen-independent and therapy-resistant phenotype. To elucidate the molecular mechanisms underlying this endocrine therapy failure, we applied retroviral insertion mutagenesis to identify the main genes conferring estrogen independence to human breast cancer cells. Estrogen-dependent ZR-75-1 cells were infected with replication-defective retroviruses followed by selection with the anti-estrogen 4-hydroxy-tamoxifen. In the resulting panel of 79 tamoxifen-resistant cell lines, the viral integrations were mapped within the human genome. Genes located in the immediate proximity of the retroviral integration sites were characterized for altered expression and their capacity to confer anti-estrogen resistance when transfected into breast cancer cells. Out of 15 candidate BCAR (breast cancer anti-estrogen resistance) genes, seven (AKT1, AKT2, BCAR1, BCAR3, EGFR, GRB7, and TRERF1/BCAR2) were shown to directly underlie estrogen independence. Our results show that insertion mutagenesis is a powerful tool to identify BCAR loci, which may provide insights into the molecular and cellular mechanisms of breast tumor progression and therapy resistance thereby offering novel targets for the development of tailor-made therapeutical and prevention strategies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
2.
Zurück zum Zitat Jaiyesimi IA, Buzdar AU, Decker DA et al (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513–529PubMed Jaiyesimi IA, Buzdar AU, Decker DA et al (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513–529PubMed
3.
Zurück zum Zitat Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101–112PubMedCrossRef Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101–112PubMedCrossRef
4.
Zurück zum Zitat Clarke R, Liu MC, Bouker KB et al (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316–7339PubMedCrossRef Clarke R, Liu MC, Bouker KB et al (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316–7339PubMedCrossRef
5.
Zurück zum Zitat Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s–870sPubMed Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s–870sPubMed
6.
Zurück zum Zitat Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247–263PubMed Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247–263PubMed
8.
Zurück zum Zitat van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef
9.
Zurück zum Zitat Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef
10.
Zurück zum Zitat Jansen MP, Foekens JA, van Staveren IL et al (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732–740PubMedCrossRef Jansen MP, Foekens JA, van Staveren IL et al (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732–740PubMedCrossRef
11.
Zurück zum Zitat Foekens JA, Atkins D, Zhang Y et al (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24:1665–1671PubMedCrossRef Foekens JA, Atkins D, Zhang Y et al (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24:1665–1671PubMedCrossRef
12.
Zurück zum Zitat Uren AG, Kool J, Berns A et al (2005) Retroviral insertional mutagenesis: past, present and future. Oncogene 24:7656–7672PubMedCrossRef Uren AG, Kool J, Berns A et al (2005) Retroviral insertional mutagenesis: past, present and future. Oncogene 24:7656–7672PubMedCrossRef
13.
Zurück zum Zitat Neil JC, Cameron ER (2002) Retroviral insertion sites and cancer: fountain of all knowledge? Cancer Cell 2:253–255PubMedCrossRef Neil JC, Cameron ER (2002) Retroviral insertion sites and cancer: fountain of all knowledge? Cancer Cell 2:253–255PubMedCrossRef
14.
Zurück zum Zitat Theodorou V, Kimm MA, Boer M et al (2007) MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 39:759–769PubMedCrossRef Theodorou V, Kimm MA, Boer M et al (2007) MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 39:759–769PubMedCrossRef
15.
Zurück zum Zitat Van Agthoven T, Van Agthoven TLA, Portengen H et al (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082–5088PubMed Van Agthoven T, Van Agthoven TLA, Portengen H et al (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082–5088PubMed
16.
Zurück zum Zitat Van Agthoven T, Van Agthoven TLA, Dekker A et al (1994) Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 8:1474–1483PubMedCrossRef Van Agthoven T, Van Agthoven TLA, Dekker A et al (1994) Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 8:1474–1483PubMedCrossRef
17.
Zurück zum Zitat Dorssers LCJ, Van Agthoven T, Dekker A et al (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7:870–878PubMedCrossRef Dorssers LCJ, Van Agthoven T, Dekker A et al (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7:870–878PubMedCrossRef
18.
Zurück zum Zitat Van Agthoven T, Van Agthoven TLA, Dekker A et al (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17:2799–2808PubMedCrossRef Van Agthoven T, Van Agthoven TLA, Dekker A et al (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17:2799–2808PubMedCrossRef
19.
Zurück zum Zitat Brinkman A, Van der Flier S, Kok EM et al (2000) BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92:112–120PubMedCrossRef Brinkman A, Van der Flier S, Kok EM et al (2000) BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92:112–120PubMedCrossRef
20.
Zurück zum Zitat Meijer D, Van Agthoven T, Bosma PT et al (2006) Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4:379–386PubMedCrossRef Meijer D, Van Agthoven T, Bosma PT et al (2006) Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4:379–386PubMedCrossRef
21.
Zurück zum Zitat Dorssers LCJ, Veldscholte J (1997) Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells. Int J Cancer 72:700–705PubMedCrossRef Dorssers LCJ, Veldscholte J (1997) Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells. Int J Cancer 72:700–705PubMedCrossRef
22.
Zurück zum Zitat Mikkers H, Allen J, Knipscheer P et al (2002) High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32:153–159PubMedCrossRef Mikkers H, Allen J, Knipscheer P et al (2002) High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32:153–159PubMedCrossRef
23.
Zurück zum Zitat Gizard F, Robillard R, Barbier O et al (2005) TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1. Mol Cell Biol 25:4335–4348PubMedCrossRef Gizard F, Robillard R, Barbier O et al (2005) TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1. Mol Cell Biol 25:4335–4348PubMedCrossRef
24.
Zurück zum Zitat Dorssers LCJ, Van Agthoven T, Brinkman A et al (2005) Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor pathway. Breast Cancer Res 7:R82–R92. doi:10.1186/bcr1954 PubMedCrossRef Dorssers LCJ, Van Agthoven T, Brinkman A et al (2005) Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor pathway. Breast Cancer Res 7:R82–R92. doi:10.​1186/​bcr1954 PubMedCrossRef
25.
Zurück zum Zitat Dorssers LCJ, Van der Flier S, Brinkman A et al (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61:1721–1733PubMedCrossRef Dorssers LCJ, Van der Flier S, Brinkman A et al (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61:1721–1733PubMedCrossRef
26.
Zurück zum Zitat Stoica GE, Franke TF, Moroni M et al (2003) Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22:7998–8011PubMedCrossRef Stoica GE, Franke TF, Moroni M et al (2003) Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22:7998–8011PubMedCrossRef
27.
Zurück zum Zitat de Graffenried LA, Friedrichs WE, Russell DH et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059–8067CrossRef de Graffenried LA, Friedrichs WE, Russell DH et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059–8067CrossRef
28.
Zurück zum Zitat Glaros S, Atanaskova N, Zhao C et al (2006) Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Mol Endocrinol 20:996–1008PubMedCrossRef Glaros S, Atanaskova N, Zhao C et al (2006) Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Mol Endocrinol 20:996–1008PubMedCrossRef
29.
Zurück zum Zitat Kairouz R, Parmar J, Lyons RJ et al (2005) Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells. J Cell Physiol 203:85–93PubMedCrossRef Kairouz R, Parmar J, Lyons RJ et al (2005) Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells. J Cell Physiol 203:85–93PubMedCrossRef
30.
Zurück zum Zitat O’Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new cas(t) of characters enters the stage. Trends Cell Biol 10:111–119PubMedCrossRef O’Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new cas(t) of characters enters the stage. Trends Cell Biol 10:111–119PubMedCrossRef
31.
Zurück zum Zitat Riggins RB, Thomas KS, Ta HQ et al (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007–7015PubMedCrossRef Riggins RB, Thomas KS, Ta HQ et al (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007–7015PubMedCrossRef
32.
Zurück zum Zitat Felekkis KN, Narsimhan RP, Near R et al (2005) AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res 3:32–41PubMed Felekkis KN, Narsimhan RP, Near R et al (2005) AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res 3:32–41PubMed
33.
Zurück zum Zitat Yu Y, Hao Y, Feig LA (2006) The R-Ras GTPase mediates cross talk between estrogen and insulin signaling in breast cancer cells. Mol Cell Biol 26:6372–6380PubMedCrossRef Yu Y, Hao Y, Feig LA (2006) The R-Ras GTPase mediates cross talk between estrogen and insulin signaling in breast cancer cells. Mol Cell Biol 26:6372–6380PubMedCrossRef
34.
Zurück zum Zitat Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926–935PubMedCrossRef Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926–935PubMedCrossRef
35.
Zurück zum Zitat Perissi V, Rosenfeld MG (2005) Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6:542–554PubMedCrossRef Perissi V, Rosenfeld MG (2005) Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6:542–554PubMedCrossRef
36.
Zurück zum Zitat Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19:1543–1554PubMedCrossRef Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19:1543–1554PubMedCrossRef
37.
Zurück zum Zitat Gizard F, Robillard R, Gross B et al (2006) TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol 26:7632–7644PubMedCrossRef Gizard F, Robillard R, Gross B et al (2006) TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol 26:7632–7644PubMedCrossRef
38.
Zurück zum Zitat Dressman HK, Hans C, Bild A et al (2006) Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12:819–826PubMedCrossRef Dressman HK, Hans C, Bild A et al (2006) Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12:819–826PubMedCrossRef
39.
Zurück zum Zitat Nicholson S, Halcrow P, Farndon JR et al (1989) Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i:182–185CrossRef Nicholson S, Halcrow P, Farndon JR et al (1989) Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i:182–185CrossRef
40.
Zurück zum Zitat Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12:104–107PubMedCrossRef Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12:104–107PubMedCrossRef
41.
Zurück zum Zitat Bellacosa A, De Feo D, Godwin AK et al (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280–285PubMedCrossRef Bellacosa A, De Feo D, Godwin AK et al (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280–285PubMedCrossRef
42.
Zurück zum Zitat Kirkegaard T, Witton CJ, McGlynn LM et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139–146PubMedCrossRef Kirkegaard T, Witton CJ, McGlynn LM et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139–146PubMedCrossRef
43.
Zurück zum Zitat Van der Flier S, Brinkman A, Look MP et al (2000) Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 92:120–127PubMedCrossRef Van der Flier S, Brinkman A, Look MP et al (2000) Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 92:120–127PubMedCrossRef
44.
Zurück zum Zitat Dorssers LCJ, Grebenchtchikov N, Brinkman A et al (2004) The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194–6202PubMedCrossRef Dorssers LCJ, Grebenchtchikov N, Brinkman A et al (2004) The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194–6202PubMedCrossRef
45.
Zurück zum Zitat Dorssers LCJ, Grebenchtchikov N, Brinkman A et al (2004) Application of a newly developed ELISA for BCAR1 Protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Clin Chem 50:1445–1447PubMedCrossRef Dorssers LCJ, Grebenchtchikov N, Brinkman A et al (2004) Application of a newly developed ELISA for BCAR1 Protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Clin Chem 50:1445–1447PubMedCrossRef
46.
Zurück zum Zitat Defilippi P, Di Stefano P, Cabodi S (2006) p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 16:257–263PubMedCrossRef Defilippi P, Di Stefano P, Cabodi S (2006) p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 16:257–263PubMedCrossRef
47.
Zurück zum Zitat Cabodi S, Tinnirello A, Di Stefano P et al (2006) p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 66:4672–4680PubMedCrossRef Cabodi S, Tinnirello A, Di Stefano P et al (2006) p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 66:4672–4680PubMedCrossRef
48.
Zurück zum Zitat Kao J, Pollack JR (2006) RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 45:761–769PubMedCrossRef Kao J, Pollack JR (2006) RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 45:761–769PubMedCrossRef
Metadaten
Titel
Functional identification of genes causing estrogen independence of human breast cancer cells
verfasst von
Ton van Agthoven
Jos Veldscholte
Marcel Smid
Thecla L. A. van Agthoven
Lilian Vreede
Marieke Broertjes
Ingrid de Vries
Danielle de Jong
Roya Sarwari
Lambert C. J. Dorssers
Publikationsdatum
01.03.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9969-5

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.